4 results
To provide continued bevacizumab therapy as single agent or in combination with an anti-cancer drug to patients with cancer, who were previously enrolled in a F. Hoffmann-La Roche (Roche)/ Genentech sponsored bevacizumab study (i.e. the Parent, P-…
1. The primary objective of this phase I/II clinical trial is to evaluate the safety and toxicity of ACT plus nivolumab according to CTCAE 4.0 criteria. Toxicity grade 3 or less and SAE related to treatment but that does not result in treatment…
This study is designed as a single-center diagnostic accuracy study. The duration of the study is 2 years. To introduce tissue sensing during the stereotactic VABB, we developed an optical introducer with DRS fibers that can be integrated with the…
This study consists of two phases. The first phase includes a pilot study for the feasibility of using this new developed smart VAE device. If this pilot study is successful we will continue to the second phase. This phase includes a proof of…